Shanghai, Mar 9, 2026 - (ACN Newswire via SeaPRwire.com) – In early March 2026, Huatai Securities held its 2026 Spring Investment Summit in Shanghai. Convened under the banner of seizing opportunity, embracing innovation and planning for the long term, the summit brought together investors, corporates and policy experts to examine market dynamics amid a period of profound structural change and to identify forward-looking investment opportunities.The two-day event featured a flagship plenary session alongside 11 sector-focused forums, addressing a broad range of market-defining topics, including the outlook for US politics, defense technology, policy interpretation following China’s “Two Sessions”, and the macroeconomic and market outlook for 2026.In her opening remarks, Dr. LIANG Hong, Chair of the Institutional Business Committee at Huatai Securities, observed that China is at a critical revival moment and delivering a strong start to the 15th Five-Year Plan will be the policy priority in 2026. A convergence of structural forces is reshaping upstream pricing dynamics and industry fundamentals: with PPI turning positive; building a unified national market; deepening supply-side rationalization reforms; the approaching 2030 carbon-peak milestone; elevated resource-security priorities; and a new direction for AI-capex. She noted that the upward re-rating of Chinese assets began in 2025 will broaden and deepen this year, with continued conviction in investment themes spanning technology, power, chemicals and rare metals amid the interplay of geopolitical realignment and the AI supercycle.Huatai Research’s macro team led in-depth discussions on the current economic backdrop, asset-allocation themes and market strategy.Focusing on key macro variables, Eva YI, Chief Economist at Huatai Securities, elaborated on what she described as a “more commodity-intensive global capex cycle” — one driven by the infrastructure build-out of AI-related capital expenditure, a renewed upcycle in global defense spending, a trough in China’s real estate construction costs, and a recovery in the global manufacturing cycle. A sustained rebound in PPI, in her view, will serve as the leading indicator of this round of asset re-rating in China.Against this backdrop, Huatai’s economics research team has recently revised up its forecasts for China’s PPI and the RMB exchange rate. Eva noted that pro-cyclical appreciation of the RMB reflects improving returns on investment and declining risk premia, potentially enabling USD-denominated earnings growth of Chinese corporates to outpace that of major developed markets for the first time since 2021 — which could structurally change global asset allocation landscape.On the core asset-allocation themes for the year, ZHANG Jiqiang, Head of Huatai Research and Chief Analyst for Fixed Income, highlighted the search for “pricing power” as a defining market narrative. The evolution of the geopolitical order and the AI revolution remain key perspectives in identifying structural opportunities. While global liquidity conditions may soften this year, RMB appreciation and the safe characteristics of Chinese markets are expected to attract capital inflows, with maturing domestic deposits providing additional liquidity support. While near-term uncertainty surrounding Iran remains a key risk, investors are shifting from pure risk-off trading sentiment to pricing in stagflation concerns, as the duration of the conflict remains the critical factor to consider.Across asset classes, ZHANG expects equities and commodities to outperform bonds. Structurally, upstream resource sectors are favored over downstream consumption, hardware over software, and export-oriented industries are likely to retain competitive momentum.Turning to China’s A-share market, HE Kang, Chief Strategist and Co-Chief for Quantitative Research at Huatai Research, pointed to two pivotal shifts — changes in the AI narrative and expectations for a return to positive PPI — that may validate the annual style call of “rebalancing between the old and new economies”. From late March into April, as macro data and corporate earnings are released, markets are likely to refocus on fundamentals. High-growth segments could cluster in cyclical sectors, manufacturing and TMT, within a backdrop of a structurally differentiated, modest recovery. Overseas expansion will remain a critical variable for earnings improvement. Should first-quarter macro data surprise to the upside, large-cap value stocks that are more sensitive to fundamental recovery could see scope for style rotation.He also highlighted that quantitative models suggest equities and commodities tend to benefit in an environment of ample liquidity and moderately rising inflation. In particular, commodities may see the resonance of short- and medium-term cycles in the second half of the year, offering stronger potential gains — a view consistent with Huatai economics research team’s broader thesis of a global commodity-intensive supercycle.On Hong Kong equities, LI Yujie, Strategist at Huatai Research, argued that the market’s primary driver in 2026 has shifted from valuation and liquidity to earnings. Expectations for profit recovery center on three themes: sectors linked to a marginal stabilization in property, such as building materials; pricing opportunities arising from tight supply-demand balances, including lithium mining, livestock and dairy, and transportation; and technological bottlenecks, with a focus on domestically developed semiconductors in the Hong Kong market.LI underscored that technology remains a clear overarching theme, with debate focused on which segments will ultimately capture value in this wave of innovation. For China’s AI ecosystem, she advised against concentrating exposure solely on upstream chips or downstream applications, advocating instead a bottom-up approach to identifying high-quality companies with competitive potential across the value chain.The plenary session also welcomed a distinguished lineup of external voices. GUO Kai, Executive President of CF40 Institute, offered his assessment of the macroeconomic outlook. ZHAO Hai, Director of the Department of International Politics at the National Institute for Global Strategy under CASS, addressed the shifting global order. XIE Suming, Member of the Strategic Advisory Committee and Chief Analyst at Yuanwang Think Tank, shared perspectives on defense technology innovation. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, March 8, 2026 - (ACN Newswire via SeaPRwire.com) – The 42nd Hong Kong International Jewellery Show and the 12th Hong Kong International Diamond, Gem & Pearl Show wrapped up successfully today. Organised by the Hong Kong Trade Development Council (HKTDC) under the “Two Shows, Two Venues” format, the twin shows together drew some 80,000 buyers from 150 countries and regions, with the Diamond, Gem & Pearl Show welcoming over 28,000 buyers from 125 countries and regions and the Jewellery Show attracting over 51,000 buyers from 140 countries and regions.Jenny Koo, Deputy Executive Director of the HKTDC, said: “The twin jewellery shows hosted about 4,000 exhibitors from more than 40 countries and regions. Buyer attendance from the Philippines, Korea, Australia and Switzerland all recorded significant growth, a testament to the strong international standing of the twin shows. Over 30 industry seminars and events were held during the shows, keeping industry professionals informed of the latest market and industry trends. We were pleased to welcome three pavilions making their debut at the show, namely the Hard Pure Gold Pavilion, the Zhushan Turquoise Pavilion and the Hong Kong Watch Manufacturers Association Pavilion, each showcasing their jewellery craftsmanship to international buyers.”Industry optimistic about Korea and ASEAN marketsTo gain deeper insights into jewellery industry trends, the HKTDC conducted an on-site survey of 1,509 exhibitors and buyers. Results indicate that both buyers and exhibitors are cautiously optimistic about the economic outlook. Key findings are:Market and industry outlook44.3% of respondents expect overall sales to increase in the next one to two years; 49% expect sales to remain stable.Respondents view the following markets as having good or very good growth potential for jewellery products over the next two years: Korea (73.2%), ASEAN (71.8%), Chinese Mainland (68.5%), Taiwan (65.3%), Australia (64.1%).For those markets with the greatest development potential, most respondents plan to explore: Europe (20.8%), ASEAN (16.8%), Chinese Mainland (15.3%), Japan (15.3%), Taiwan (10.8%).In the next three years, technological advancements in artificial intelligence (66.1%), social media (43.7%), and big data (41.5%) are expected to have the greatest impact on the jewellery industry.Product trendsProducts with the strongest growth potential this year include trendy fashion jewellery (57.3%), precious jewellery (35.1%), and designer jewellery (21.1%).The most popular precious metal products in 2026 are karat yellow gold (40.1%), karat white gold (31.7%) and pure gold (28%).The most popular gemstones this year are diamonds (28.8%), followed by rubies (24.7%) and pearls (19.7%).Riding the gold wave: Chinese Mainland hard pure gold makers go globalThe government’s latest Budget Speech highlighted plans to strengthen Hong Kong’s status as an international gold trading market which is expected to bring new momentum to gold demand in the jewellery market. Adding to the excitement, the World Gold Council led 10 exhibitors from the Chinese Mainland for the first time to launch the Hard Pure Gold Pavilion at this year’s show, which proved to be one of the show's major highlights.Regional CEO Roland Wang said: “The Hong Kong International Jewellery Show has been instrumental in helping Chinese gold manufacturers connect with international buyers and expand their market reach. We have already received a considerable number of orders in just the first three days. Our current focus is on developing markets in Southeast Asia, the Middle East and India, where interest in hard pure gold products is steadily growing. More affordable, lighter-weight hard pure gold pieces are proving particularly attractive to younger middle-class consumers.”Sharon Weng, Deputy General Manager of YueHao Jewellery, a Shenzhen-based exhibitor at the Hard Pure Gold Pavilion, said: “Expanding our overseas client base is a key business priority for us this year, and the show has provided the ideal platform to pursue that goal. We have also established connections with Southeast Asian markets, including Malaysia, Singapore and Thailand." Another Chinese Mainland exhibitor specialising in hard pure gold jewellery expressed plans to set up an office in Hong Kong in the near future, to better leverage the city as a springboard for global expansion.Sales surpass expectations as diamonds captivate buyersSales at the shows this year exceeded expectations for many exhibitors. Youngeun Kim, founder of Soyou, a Korean exhibitor, said: "Through the world's largest jewellery trade platform, we have successfully connected with potential buyers from the Chinese Mainland, Africa and the United Kingdom, and expect our sales to grow by 30% compared with last year."Hong Kong exhibitor SimStar Asia Limited, which specialises in high-value, investment-grade diamonds, secured several orders from buyers in Europe and the United States during the show, with total transactions running into the millions of US dollars. The company also projected a 10% increase in annual sales and noted that demand for high-clarity, top-colour white diamonds in the 5 to 10-carat range remains robust, while rare red and blue diamonds are also drawing keen interest from buyers.This year, the Hall of Fame grew by more than 40%. Emre Can, Export Sales Manager of Zen Diamond, a Turkish exhibitor, shared that while the company initially came with the aim of expanding into Asian markets, buyers from the United Kingdom and the United States had already expressed interest on Day One. Existing clients from Europe and South America also travelled to meet face to face, which is a testament to the global appeal of branded jewellery.Designer jewellery on the rise as new generation embraces personalisationThe shows welcomed over 50 designer exhibitors, including 10 Korean designers making their debut at the fair. They were pleased with their results and are already considering expanding their presence at next year's edition. A Korean designer exhibitor also shared that new enquiries from potential buyers had been received, particularly from Europe, and was pleasantly surprised to receive one from Poland. A seminar featuring Paola De Luca, Founder and Creative Director of Trendvision Jewellery + Forecasting, gave attendees an in-depth look at emerging jewellery design trends, exploring how personalisation can respond to the younger consumer market.The shows also hosted three design competitions: the 27th Hong Kong Jewellery Design Competition, the Hong Kong International Fashion Chuk Kam Jewellery Design Competition, and the inaugural International Fei Cui Jewellery Design Competition. Award ceremonies were held on-site, with winning pieces on display across the venue, offering buyers a first look at the latest creative works while fostering closer ties between designers and jewellery manufacturers.Global exhibitors tap into new opportunitiesThe twin shows brought together exhibitors from around the world, with Uzbekistan making its debut appearance. Fonon Jewelry House, an Uzbek exhibitor, showcased gold pieces with distinctive Central Asian cultural influences, drawing strong interest from international buyers. Alisher Romanov, the Head of Foreign Economic Affairs of this exhibitor, said: "We are looking to use Hong Kong as a springboard for expansion into other Asian markets. We have already connected with potential buyers from the Chinese Mainland, Malaysia and the Philippines, and expect sales to reach approximately USD 50 million." Another Uzbek exhibitor also shared that it had received a jewellery order worth as much as USD 35 million from a Hong Kong buyer. The Uzbekistan delegation also seized the occasion to formally sign a Memorandum of Understanding (MOU) with the HKTDC and the Hong Kong Jewellery Manufacturers' Association, with the aim of further promoting Uzbekistan's jewellery to global markets through Hong Kong's platform and strengthening bilateral trade ties.Buyers seek diverse offeringsTurkish buyer, Kasapoglu Jewellery came to the show with the specific goal of sourcing new loose diamond suppliers, setting aside a procurement budget of over USD 900,000. US-based diamond wholesaler David Abraham & Co found the show to be a true one-stop destination, discovering services ranging from certification to repolishing, as well as sourcing gemological equipment and tools. The company met with 35 exhibitors from Hong Kong, India, Israel, the Middle East, Europe and the United States in a single day. China National Gold Group Gold Jewellery Co., Ltd. from Beijing made the most of both shows, sourcing turquoise samples at the Diamond, Gem & Pearl Show and explored fine jewellery offerings at the Jewellery Show. The company noted that demand for both high-end gemstones and mass-market jewellery is growing in tandem, with younger consumers increasingly drawn to delicate and refined designs. Its total procurement budget across both shows is USD 200,000.Golden Silver Z.L S.A., a major 925 sterling silver jewellery supplier in Latin America and a loyal visitor to the shows for over 20 years, returned again this year and confirmed silver jewellery orders with three exhibitors, with combined transactions exceeding USD 1.9 million.Online-offline integration expands horizonsDue to the impact of geopolitical situation, some buyers from certain regions were unable to attend in person. The HKTDC responded promptly with a range of support measures. These included on-site support for exhibitors with promotional material placement, as well as helping affected buyers rearrange flights and accommodation to defer their arrivals by one to two days.Meanwhile, the shows continue to adopt the EXHIBITION+ online and offline hybrid format, enabling enterprises to extend their physical exhibition negotiations to online matching platforms. Exhibitors and buyers can engage in AI-powered business matching through the HKTDC Marketplace App's "Click2Match" and hktdc.com Sourcing, while buyers can also use Scan2Match to scan exhibitors’ QR codes and continue discussions with exhibitors online after the show.For buyers from affected regions who were unable to travel to Hong Kong for sourcing, the show facilitated over 100 online business matching sessions, helping the industry sustain momentum and seize opportunities during a challenging period.The HKTDC continues to help exhibitors tap into the Chinese Mainland market through e-commerce channels. This year, two major platforms, Taobao Tmall and, for the first time, Douyin partnered with the shows, involving 10 exhibitors and more than 30 influencers and KOLs. The campaign generated over 35 million online impressions and achieved sales exceeding USD 20 million. The shows also invited Korean influencer to attend, who successfully sourced from a number of exhibitors, with combined purchases totalling close to USD 700,000.Photo download: https://bit.ly/4aXXZ24Organised by the HKTDC, the 42nd Hong Kong International Jewellery Show and 12th Hong Kong International Diamond, Gem & Pearl Show have concluded successfullyThe world’s one-stop jewellery marketplace is highly regarded by industry professionals worldwide, with buyers demonstrating strong purchasing intentThe Uzbekistan delegation made its debut at the Hong Kong International Jewellery Show this year. It also signed an MOU with the HKTDC and the Hong Kong Jewellery Manufacturers' Association to further promote Uzbekistan's jewellery to global markets through Hong Kong's platformDouyin participated in the Hong Kong International Jewellery Show for the first time, enabling exhibitors to tap into the Chinese Mainland marketThe twin jewellery shows covered the entire industry supply chain, from raw materials and design to finished pieces, setting, packaging and gemological instruments — all under one roof.The jewellery parades highlighted the latest creative designs, fostering connections across the industryThe 27th Hong Kong Jewellery Design Competition, themed "Pure Elegance – Natural Beauty", showcased the talents of local professional jewellery designers and students, with multiple designers receiving awards for their exceptional entries.At the award ceremony of the International Fei Cui Jewellery Design Competition, themed "A New Legacy of Jade, Design Without Boundaries", outstanding designers who blend jadeite craftsmanship with international culture were honoured.Over 30 industry seminars and networking events were held during the twin jewellery showsWebsites Hong Kong International Diamond, Gem & Pearl ShowHong Kong International Jewellery ShowExhibition websitehttps://www.hktdc.com/event/hkdgp/enhttps://www.hktdc.com/event/hkjewellery/enHighlighted productshttps://tinyurl.com/2vtknn2r HKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact HKTDC’s Communication & Public Affairs Department:Winnie KanTel: (852) 2584 4055Email: winnie.wy.kan@hktdc.orgKaty WongTel: (852) 2584 4524Email: katy.ky.wong@hktdc.orgJane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Mar 9, 2026 - (ACN Newswire via SeaPRwire.com) - AI Labs, an AI-driven crypto trading technology company backed by Academic Labs, announced the launch of an AI-assisted platform designed to help cryptocurrency traders analyze market data and respond more efficiently to changing market conditions. As automated tools and algorithmic strategies become more common in global digital asset markets, the platform integrates visual analysis, narrative data monitoring, and automated trade execution features intended to support more structured and data-driven trading decisions.The fastest traders in today's crypto markets may not always be humans. As digital asset markets increasingly incorporate automation, many traders now rely on algorithmic systems that can monitor markets continuously and react to signals with minimal delay.A crypto project called AI Labs (ticker: AIX) is building an AI-enabled platform that combines visual reasoning, narrative intelligence, and automated execution to help users interpret market data and respond to signals more efficiently than traditional manual analysis alone."Markets are entering an era where the use of artificial intelligence is becoming more common in trading strategies," said Kingston Kwek, owner of AI Labs. "Our goal is to make analytical tools that are often used by institutional trading teams more accessible to a wider group of crypto traders."At the center of AI Labs' platform is a visual reasoning engine that analyzes charts not simply as static images, but as evolving market structures.Using computer vision and multimodal AI techniques, the system can identify potential liquidity zones, resistance levels, and broader market patterns within short timeframes.Alongside this, AI Labs has developed a narrative intelligence layer that scans information across the crypto ecosystem. This includes movements associated with large crypto wallets, developer updates, and shifts in online sentiment—signals that traders often monitor when assessing possible market trends.Instead of only placing individual buy or sell orders, traders can define broader trading parameters using the AI system. The platform can then execute trades automatically based on predefined conditions, such as capital inflows, volatility changes, or funding-rate shifts.The objective is to help reduce emotional decision-making and allow traders to stay aligned with their strategies while automated systems monitor market activity continuously.AI Labs' platform is currently onboarding new users, with reported monthly trading activity exceeding $1 billion across the platform.Media ContactBrand: AI Labs (Backed by Academic Labs)Contact: Media teamWebsite: https://academic-labs.org Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- First glucokinase-activator (GKA) approval outside mainland China- Approval supports a differentiated approach to Type 2 diabetes (T2D) management- Hong Kong will serve as Hua Medicine’s launchpad for international market expansionSHANGHAI, HONG KONG, Mar 3, 2026 - (ACN Newswire via SeaPRwire.com) – Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552.HK) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS(R)) has been approved for marketing by the Pharmaceutical Service of the Department of Health of the Hong Kong Special Administrative Region of China for the treatment of Type 2 diabetes in adults.Under Hong Kong's "1+" pharmaceutical regulatory innovation mechanism, the approval follows the acceptance of dorzagliatin’s New Drug Application (NDA) by the Hong Kong Department of Health in September 2025. As the first innovative drug for chronic metabolic diseases approved for marketing since the launch of "1+" mechanism, the successful rollout of dorzagliatin not only brings an entirely new treatment option for patients with Type 2 diabetes in Hong Kong, but also marks a crucial step in Hua Medicine's strategic layout to expand from China to the Southeast Asian and global markets with Hong Kong as its hub.Cao Beili, Vice President of Department of Corporate Operation and Great Bay Development of Hua Medicine, stated: “Among the three new drugs approved under the ‘1+’ mechanism, MYHOMSIS(R) is an innovative medicine developed in China that has obtained approval from the National Medical Products Administration (NMPA). It is also the first primary care drug product approved under the ‘1+’ mechanism.”Dr. Chen Li, Founder, Executive Director and CEO of Hua Medicine, stated: "The approval of dorzagliatin for marketing in Hong Kong is a significant milestone in the Company's development. As one of the first original innovative drugs to benefit from Hong Kong's '1+' mechanism, this achievement not only reflects Hong Kong's support for innovative drugs, but also validates the global competitiveness of China's independently developed innovative drugs. The launch in Hong Kong is a key step for Hua Medicine to enter the Southeast Asian and international markets. We will take Hong Kong as the hub to build a marketing network and R&D cooperation system radiating Southeast Asia and connecting the world, bringing China's independently developed innovative drugs to more diabetes patients in countries and regions around the globe. Meanwhile, we will continue to advance the marketing approval process of dorzagliatin in the Macao Special Administrative Region of China to achieve its full rollout in the Guangdong-Hong Kong-Macao Greater Bay Area, and relying on the regional advantages in mechanisms, talent and medical resources, we will advance the clinical expansion of new indications and the international promotion of MYHOMSIS(R)."Global First-in-Class & Local Clinical Data: Establishing a New Model for Restoring Glycemic Homeostasis in Diabetes TreatmentType 2 diabetes remains a progressive disease characterized by impaired glucose regulation and declining pancreatic β-cell function over time. While many therapies address downstream consequences of dysregulated blood glucose, dorzagliatin is a global first-in-class GKA innovative drug independently developed by Hua Medicine. Its core innovation lies in repairing the impaired function and expression of glucokinase (GK) in patients with Type 2 diabetes, thereby improving patients' glucose sensitivity from the source and ameliorating the imbalance of glycemic homeostasis. The drug acts on multiple key organs of glucose metabolism including the islets, intestines and liver, exerting a synergistic effect through multiple targets:- enhancing glucose-stimulated insulin secretion from pancreatic β-cells, - promoting GLP-1 release from intestinal L-cells, and - modulating hepatic glucose output through glycogen regulation.This coordinated, multi-organ profile differentiates dorzagliatin from existing oral antidiabetic therapies and reflects Hua Medicine’s focus on addressing glucose homeostasis dysregulation and controlling the progression of Type 2 diabetes and the occurrence of its complications from the source.Dorzagliatin was approved for marketing by the China National Medical Products Administration (NMPA) in September 2022 for two indications, both to improve blood glucose control for T2D patients:1) It can be used as mono-therapy treatment for drug-naïve T2D patients, as first-line treatment,2) When metformin hydrochloride alone exhibits poor blood glucose control in T2D patients, it can be used in combination with metformin hydrochloride.Since January 1, 2024, dorzagliatin is included in China’s National Reimbursement Drug List and has been prescribed to over 200,000+ patients in mainland China already. In June last year, the interim analysis of real-world research presented at the Scientific Sessions of the American Diabetes Association (ADA) further verified its efficacy and safety in a broad population.Leveraging Hong Kong's "1+" Mechanism to Accelerate Access to Innovative Drugs for Hong Kong ResidentsThe formulation and implementation of Hong Kong's "1+" pharmaceutical regulatory innovation mechanism is an important measure taken by the Hong Kong SAR Government to enhance the accessibility of medical innovation and attract high-quality global innovative drugs to launch in Hong Kong. This mechanism allows innovative drugs already approved in designated major markets (such as China, the United States, Europe, etc.) to secure marketing approval in Hong Kong through a simplified application pathway and data mutual recognition mechanism, which greatly shortens the time cycle from R&D to clinical access of innovative drugs for Hong Kong patients, while ensuring the safety and efficacy of the drugs.With its local clinical data, clear therapeutic value and good safety record in China, dorzagliatin has become one of the first original Chinese innovative drugs to be rapidly approved through Hong Kong's "1+" mechanism. This approval is an important practical achievement of the mechanism in enabling the launch of global innovative drugs in Hong Kong, which not only reflects the high recognition of the clinical value of dorzagliatin by the Department of Health of Hong Kong, but also highlights the core role of the "1+" mechanism in connecting the Chinese market and international pharmaceutical markets and accelerating the flow of innovative medical resources.Building on Hong Kong's Experience to Empower Global Diabetes ManagementDiabetes is a major challenge for global public health. According to the 2025 Global Diabetes Map released by the International Diabetes Federation (IDF), the number of adults aged 20-79 with diabetes worldwide reached 589 million in 2024, and this figure is projected to rise to 853 million by 2050. In Hong Kong, China, diabetes is also a prominent public health issue. According to the Population Health Survey 2020-2022 conducted by the Department of Health of Hong Kong, 6.9% of people aged 15 or above reported having been diagnosed with diabetes by a doctor, and an additional 1.8% had hyperglycemia without being diagnosed with diabetes. In 2022, more than 600 death registrations in Hong Kong were attributed to diabetes, ranking 11th among the leading causes of death.[1]Hong Kong has accumulated rich experience in diabetes management, forming a comprehensive system covering disease surveillance, prevention, screening, treatment and community management, and its community-based public-private partnership model for diabetes management has achieved remarkable results. Following its launch in Hong Kong, dorzagliatin is expected to be deeply integrated with the local mature diabetes management system, and help improve patients' quality of life, control disease progression and reduce medical burdens through personalized treatment plans.At present, Hua Medicine is collaborating with the research team led by Professor Juliana Chan, a world-renowned endocrinologist from the Chinese University of Hong Kong, to conduct the SENSITIZE series of studies to further explore the mechanism by which dorzagliatin improves pancreatic β-cell glucose sensitivity. The published results of the SENSITIZE 1/2 studies have shown that dorzagliatin can significantly improve the second-phase insulin secretion and β-cell glucose sensitivity in patients with glucokinase monogenic diabetes (GCK-MODY or MODY-2), and enhance basal insulin secretion in patients with newly diagnosed type 2 diabetes. In addition, dorzagliatin can also significantly improve the second-phase insulin secretion and β-cell glucose sensitivity in populations with impaired glucose tolerance (IGT).Hua Medicine will continue to deepen cooperation with top local research institutions and clinicians to further explore the potential of dorzagliatin in pre-diabetes intervention, early treatment and complication prevention, accumulate additional international clinical data, lay a solid foundation for the expansion of its indications and global market promotion, and establish personalized intervention and treatment management plans for patients with pre-diabetes and Type 2 diabetes.As a core hub of the Asian pharmaceutical market, Hong Kong, with its unique geographical location, advanced medical infrastructure, international business environment and close linkage with the Southeast Asian market, is expected to become the strategic starting point for Hua Medicine to expand into Southeast Asia and the global market. Relying on Hong Kong's advantage of pharmaceutical regulatory standards aligned with international norms and leveraging its financial and capital market strengths, Hua Medicine will further advance the registration and application of dorzagliatin in the Southeast Asian market to quickly cover the large population of diabetes patients in the region. Meanwhile, the Company will deepen cooperation with partners in the global pharmaceutical industry chain to accelerate the international commercialization of dorzagliatin.Forward-Looking StatementsThis document contains statements regarding Hua Medicine's and its products' future expectations, plans and prospects. Such forward-looking statements relate only to events or information as of the date on which the statements are made in this document and are subject to change in light of future developments. Except as required by law, the Company shall not be obligated to update or publicly revise any forward-looking statements or unforeseen events after the date of such statements, whether as a result of new information, future events or other circumstances. Please read this document carefully and understand that actual future performance or results of the Company may differ materially from expectations due to various risks, uncertainties or other statutory requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment. In February 2026, dorzagliatin (Trade name: MYHOMSIS(R)) was approved for marketing by the Pharmaceutical Services of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsEmail: ir@huamedicine.comMediaEmail:pr@huamedicine.com[1] https://www.chp.gov.hk/sc/features/37474.html Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, March 3, 2026 - (ACN Newswire via SeaPRwire.com) – On 02 March 2026, Concord New Energy Group (“CNE Group”) signed a Memorandum of Understanding (MOU) in Singapore with Bridge Data Centres (BDC), a portfolio company of Bain Capital.Under the MOU, the parties will jointly explore diversified energy supply pathways integrating renewable energy and hydrogen solutions on a global basis to support the low-carbon transformation of data centre infrastructure. The collaboration includes the development of Singapore’s first barge-based hydrogen power generation solution designed specifically for artificial intelligence (AI) digital infrastructure.The partnership will encompass hydrogen power pathway studies, system integration design, energy storage deployment assessments, and optimization of power procurement mechanisms. Through these initiatives, both parties aim to enhance energy reliability, operational flexibility, and long-term sustainability for next-generation data centre campuses.CNE brings extensive expertise in renewable energy development and integrated energy systems, while BDC contributes leading operational capabilities in digital infrastructure. The collaboration is expected to accelerate the convergence of clean energy solutions and advanced computing infrastructure.As artificial intelligence and high-performance computing continue to reshape regional economies, this partnership will further support Singapore’s ambition to remain a leading digital hub powered by low-carbon energy.Bridge Data Centres (BDC)Headquartered in Singapore, Bridge Data Centres (BDC) is a leading hyperscale data centre platform in the Asia Pacific region backed by Bain Capital. The company focuses on the development and operation of high-performance digital infrastructure across multiple high-growth markets. BDC is committed to delivering resilient, reliable, and sustainable infrastructure solutions to support the rapid growth of cloud computing and artificial intelligence (AI) applications.Concord New Energy Group (CNE)Headquartered in Singapore, Concord New Energy Group is a renewable energy developer and operator listed on the Main Board of the Hong Kong Stock Exchange and the Singapore Exchange. With 20 years of experience in the renewable energy industry, CNE’s portfolio covers wind power, photovoltaic (PV) and energy storage projects. The Group has strong capabilities in project development, investment, construction and long-term asset management, and currently holds over 5GW of equity capacity globally. CNE remains committed to promoting the application of clean energy and providing integrated energy solutions to support sustainable development. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

LOS ANGELES, CA, Mar 3, 2026 - (ACN Newswire via SeaPRwire.com) - Pacific Avenue Capital Partners ("Pacific Avenue"), a Los Angeles-headquartered private equity firm focused on corporate carve-outs and other complex transactions in the middle market, today announced that an affiliate of Pacific Avenue has entered into an agreement to acquire Care.com from IAC Inc. (NASDAQ:IAC).Care.com is a leading platform and brand in the growing $400 billion market for family care, anchored by the largest online network of background-checked child and senior caregivers in the U.S.Care.com operates both a scaled consumer marketplace and an enterprise benefits platform. Since 2007, more than 45 million people have turned to Care.com to find child care, senior care, pet care and housekeeping support. Care.com also partners with more than 700 employers, including many of the Fortune 100, to deliver care-related benefits that combine access to the Care.com platform and comprehensive backup care solutions provided in-home, in-center and through camps and activities, along with a broader suite of care support solutions.As a standalone company, Care.com will accelerate its enterprise expansion while continuing to strengthen its consumer marketplace. With Pacific Avenue's investment and support, the Company will move faster on product innovation, scale its employer partnerships, and enhance the platform experience for the millions of families and caregivers who rely on it."We are thrilled to announce the Care.com transaction, the first investment in Pacific Avenue Fund II. The transaction aligns perfectly with Pacific Avenue's track record of executing corporate carve-outs to acquire market-leading businesses. Care.com is an industry leader with a brand built on trust, a strong reputation, and a proven leadership team. Care.com has a clear path for growth as an independent, standalone company. We're excited to work with Brad, Michelle, and the Care.com team to unlock the company's full potential in serving families, caregivers, and its enterprise partners."- Chris Sznewajs, Founder and Managing Partner of Pacific Avenue"Caregiving is foundational to how families live and how businesses operate," said Brad Wilson, CEO of Care.com. "This partnership allows us to deepen our support for families and caregivers while expanding the ways we serve employers who recognize that caregiving is a workforce issue. We're entering this next chapter with strength, clarity, and a renewed commitment to building the most beloved platform for care.""Care.com enters this next chapter with a profitable foundation. This transaction positions us to further invest in our platform, expand our employer partnerships, and scale efficiently while maintaining the financial discipline that has strengthened our performance," said Michelle Arbov, Chief Financial Officer of Care.com.The transaction is subject to customary closing conditions and is expected to be completed in the first half of 2026.Moelis & Company LLC served as exclusive financial advisor to Pacific Avenue. Weil, Gotshal & Manges LLP served as legal advisor to Pacific Avenue.KPMG LLP provided accounting and tax advisory services. J.P. Morgan Securities LLC acted as exclusive financial advisor to IAC and Latham and Watkins LLP served as legal counsel to IAC.About Pacific Avenue Capital PartnersPacific Avenue Capital Partners is a global private equity firm headquartered in Los Angeles with an office in Paris. The firm is focused on corporate divestitures and other complex situations in the middle market. Pacific Avenue has extensive M&A and operations experience, allowing the firm to navigate complex transactions and unlock value through operational improvement, capital investment, and accelerated growth. Pacific Avenue takes a collaborative approach in partnering with strong management teams to drive lasting and strategic change while assisting businesses in reaching their full potential. Pacific Avenue has approximately $3.8 billion of Assets Under Management (AUM) as of September 30, 2025. For more information, please visit www.pacificavenuecapital.com.Contact InformationChris BaddonManaging Directorcbaddon@pacificavenuecapital.comSOURCE: Pacific Avenue Capital Partners Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com